Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Ads

You May Also Like

AroCell is a member of SwedenBIO

AroCell became this week a member of SwedenBIO, an industry organization for Swedish Life ...

BK Ultrasound, Powered by Analogic, Introduces bkFusion at EAU 2017

PEABODY, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Analogic Corporation (Nasdaq:ALOG), enabling the world's ...